WALTHAM, Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials ( RECONNECT ) and its voluntary open-label one year extension studies were published in Obstetrics &...

WALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG”) today announced that it has entered into a settlement agreement with Caligan Partners LP (“Caligan”). As part of this agreement, the Board of Directors has appoin...

Company Thesis The FDA’s AdCom meeting this October with regards to a clinical review of Makena’s updated efficacy and safety profiles is likely to result in a total withdrawal of the product from the market. On the other hand, Amag's ( AMAG ) recent Vyleesi launch for the tr...